Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
(NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable future.
You know the company perhaps better than you realize. Blockbuster drugs like cancer-fighting Ibrance, pneumonia vaccine Prevnar, and blood-thinner Eliquis are all part of Pfizer's portfolio.
None of them hold a candle to Pfizer's (and the world's) best-selling drug of all time, of course. That's anti-cholesterol treatment Lipitor, which finally lost its patent protection in late 2011. The company has not been quite the same since, unable to replace Lipitor's revenue with any single drug. The stock has lagged accordingly.
Source Fool.com
Pfizer Inc. Aktie
Klares Buy-Übergewicht bei der Pfizer Inc. Aktie mit 29 zu 4 Einschätzungen.
Das von der Community festgelegte Kursziel für Pfizer Inc. von 41 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 27.88 €.
